Nektar Therapeutics (NKTR) Tops Q4 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500, Nasdaq pare declines as AI rout teeters; healthcare, staples gain
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $37.78 +2.41%
Revenue Growth %: -13.0%
Financial Fact:
Total revenue: 36.34M
Today's EPS Names:
NTRP, FMCB, LOOP, More
Revenue Growth %: -13.0%
Financial Fact:
Total revenue: 36.34M
Today's EPS Names:
NTRP, FMCB, LOOP, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of $0.03, $0.19 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $29.2 million versus the consensus estimate of $29.81 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Slew of analyst comments sends Take-Two (TTWO) up 4% ahead of November earnings and GTV 6
- Popular stocks with increasing option volume: CRWV SPCX INTC MU IREN WULF NBIS PLTR MSTR SOFI NFLX HOOD ORCL
- Krystal Biotech (KRYS) PT Raised to $416 at Citi
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
